In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

We came across a bullish thesis on Illumina, Inc. (ILMN) on Stock Analysis Compilation’s Substack. In this article, we will ...

MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader ...

Illumina, Inc. will acquire SomaLogic for $350 million plus performance-based milestones. The acquisition advances Illumina's multiomics strategy, combining SomaLogic's proteomics technology with ...

Illumina is estimated to have around 80% of the global DNA sequencing market, with Element one of a new generation of rivals alongside the likes of PacBio and Singular Genomics, which launched ...

Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics ...

Illumina expects the addition of a high-margin revenue stream, although the deal is expected to close in 2026.

Almost all cervical cancers are caused by human papillomaviruses (HPVs). In most cases, HPV DNA is integrated into the human genome. We found that tumor-specific, HPV-human DNA junctions are ...